A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation

Marc Miravitlles; P M Calverley; Katia M.C. Verhamme; Michael  Dreher; Valentina  Bayer; Asparuh Gardev; Alberto  de la Hoz; Jadwiga A Wedzicha; David Price

doi:10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A2251

A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation

Marc Miravitlles^* (Corresponding Author), P M Calverley, Katia M.C. Verhamme, Michael Dreher, Valentina Bayer, Asparuh Gardev, Alberto de la Hoz, Jadwiga A Wedzicha, David Price

^*Corresponding author for this work

Research output: Contribution to journal › Abstract › peer-review

35 Downloads (Pure)

Abstract

Recent studies report a possible mortality benefit of treatment with long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 moderate or severe exacerbation in the previous year). We compared the time to all-cause mortality with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderateto-severe COPD and a predominantly lower exacerbation risk.

Original language	English
Article number	A2251
Number of pages	1
Journal	American Journal of Respiratory and Critical Care Medicine
Volume	203
Early online date	19 May 2021
DOIs	https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A2251
Publication status	Published - 2021
Event	ATS International Conference Committee: ATS 2021 - Virtual event Duration: 14 May 2021 → 19 May 2021 https://conference.thoracic.org/

Access to Document

10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A2251Licence: Unspecified

Miravitlles_et_la_ATS2021_APooledAnalysisOfMortality_AAM
Originally Published in: [Authors]. [Article Title]. [Journal Name] [Year];[Volume]:[Pages]. DOI: [Number] Copyright © 2021 by the American Thoracic Society The final publication is available at [Link].
Accepted author manuscript, 188 KBLicence: Other

Cite this

Miravitlles, M., Calverley, P. M., Verhamme, K. M. C., Dreher, M., Bayer, V., Gardev, A., de la Hoz, A., Wedzicha, J. A., & Price, D. (2021). A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation. American Journal of Respiratory and Critical Care Medicine, 203, [A2251]. https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A2251

A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation. / Miravitlles, Marc (Corresponding Author); Calverley, P M; Verhamme, Katia M.C.; Dreher, Michael ; Bayer, Valentina ; Gardev, Asparuh; de la Hoz, Alberto ; Wedzicha, Jadwiga A; Price, David.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 203, A2251, 2021.

Research output: Contribution to journal › Abstract › peer-review

Miravitlles, M, Calverley, PM, Verhamme, KMC, Dreher, M, Bayer, V, Gardev, A, de la Hoz, A, Wedzicha, JA & Price, D 2021, 'A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation', American Journal of Respiratory and Critical Care Medicine, vol. 203, A2251. https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A2251

@article{b3983900573c4f1cbb7849be91688004,

title = "A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation",

abstract = "Recent studies report a possible mortality benefit of treatment with long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 moderate or severe exacerbation in the previous year). We compared the time to all-cause mortality with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderateto-severe COPD and a predominantly lower exacerbation risk.",

author = "Marc Miravitlles and Calverley, {P M} and Verhamme, {Katia M.C.} and Michael Dreher and Valentina Bayer and Asparuh Gardev and {de la Hoz}, Alberto and Wedzicha, {Jadwiga A} and David Price",

year = "2021",

doi = "10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A2251",

language = "English",

volume = "203",

journal = "American Journal of Respiratory and Critical Care Medicine",

issn = "1073-449X",

publisher = "American Thoracic Society - AJRCCM",

note = "ATS International Conference Committee : ATS 2021 ; Conference date: 14-05-2021 Through 19-05-2021",

url = "https://conference.thoracic.org/",

}

TY - JOUR

T1 - A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation

AU - Miravitlles, Marc

AU - Calverley, P M

AU - Verhamme, Katia M.C.

AU - Dreher, Michael

AU - Bayer, Valentina

AU - Gardev, Asparuh

AU - de la Hoz, Alberto

AU - Wedzicha, Jadwiga A

AU - Price, David

PY - 2021

Y1 - 2021

N2 - Recent studies report a possible mortality benefit of treatment with long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 moderate or severe exacerbation in the previous year). We compared the time to all-cause mortality with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderateto-severe COPD and a predominantly lower exacerbation risk.

AB - Recent studies report a possible mortality benefit of treatment with long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 moderate or severe exacerbation in the previous year). We compared the time to all-cause mortality with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderateto-severe COPD and a predominantly lower exacerbation risk.

U2 - 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A2251

DO - 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A2251

M3 - Abstract

VL - 203

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

M1 - A2251

T2 - ATS International Conference Committee

Y2 - 14 May 2021 through 19 May 2021

ER -

A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation

Abstract

Access to Document

Fingerprint

Cite this